Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia

Neurobiology of Aging

Volumn 29, Issue 3, 2008, Pages 379-396

  Bychkov, E R ^a,d   Gurevich, V V ^a   Joyce, J N ^b   Benovic, J L ^c   Gurevich, E V ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Brain Ctr and Inst for Human Brain   (Russian Federation)

Author keywords

Arrestin; G proteins coupled receptor kinases; Parkinson's disease; Parkinson's disease with dementia; Signaling mechanisms

Indexed keywords

DOPAMINE; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 3; G PROTEIN COUPLED RECEPTOR KINASE 5; MESSENGER RNA; RETINA S ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DEMENTIA; HUMAN; HUMAN TISSUE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIBONUCLEASE PROTECTION ASSAY; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ARRESTINS; COHORT STUDIES; DEMENTIA; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 3; G-PROTEIN-COUPLED RECEPTOR KINASE 5; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSTMORTEM CHANGES; UP-REGULATION;

EID: 38949138075     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.10.012     Document Type: Article

References (103)

1. Aarsland D., Perry R., Brown A., Larsen J.P., and Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann. Neurol. 58 (2005) 773-776
2. Ahn S., Nelson C.D., Garrison T.R., Miller W.E., and Lefkowitz R.J. Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc. Natl. Acad Sci. U.S.A. 100 (2003) 1740-1744
3. Apaydin H., Ahlskog J.E., Parisi J.E., Boeve B.F., and Dickson D.W. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 59 (2002) 102-112
4. Arriza J.L., Dawson T.M., Simerly R.B., Martin L.J., Caron M.G., Snyder S.H., and Lefkowitz R.J. The G-protein-coupled receptor kinases bARK1 and bARK2 are widely distributed at synapses in rat brain. J. Neurosci. 12 (1992) 4045-4055
5. Attramadal H., Arriza J.L., Aoki C., Dawson T.M., Codina J., Kwatra M.M., Snyder S.H., Caron M.G., and Lefkowitz R.J. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J. Biol. Chem. 267 (1992) 17882-17890
6. Bawa T., Altememi G.F., Eikenburg D.C., and Standifer K.M. Desensitization of alpha 2A-adrenoceptor signaling by modest levels of adrenaline is facilitated by beta 2-adrenoceptor-dependent GRK3 up-regulation. Br. J. Pharmacol. 138 (2003) 921-931
7. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., and Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 5099-5104
8. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., and Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122 (2005) 261-273
9. Benovic J.L., and Gomez J. Molecular cloning and expression of GRK6. A new member of the G protein-coupled receptor kinase family. J. Biol. Chem. 268 (1993) 19521-19527
10. Bezard E., and Gross C.E. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog. Neurobiol. 55 (1998) 93-116
11. Bezard E., Gross C.E., and Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 26 (2003) 215-221
12. Bezard E., Gross C.E., Qin L., Gurevich V.V., Benovic J.L., and Gurevich E.V. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol. Dis. 18 (2005) 323-335
13. Bohn L.M., Lefkowitz R.J., Gainetdinov R.R., Peppel K., Caron M.G., and Lin F.T. Enhanced morphine analgesia in mice lacking beta-arrestin2. Science 286 (1999) 2495-2498
14. Boller F., Mizutani T., Roessmann U., and Gambetti P. Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Ann. Neurol. 7 (1980) 329-335
15. Bonelli S.B., Ransmayr G., Steffelbauer M., Lukas T., Lampl C., and Deibl M. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 63 (2004) 376-378
16. Braak H., Braak E., Yilmazer D., De Vos R.A.I., Jansen E.N.H., and Bohl J. New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. J. Neural. Transm. Suppl. 48 (1996) 1-6
17. Braak H., and Braak E. Staging of Alzheimer-related cortical destruction. Int. Psychogeriatr. 9 Suppl. 1 (1997) 257-261
18. Burn D.J., Rowan E.N., Minett T., Sanders J., Myint P., Richardson J., Thomas A., Newby J., Reid J., O'Brien J.T., and McKeith J.G. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative stud. Mov. Disord. 18 (2003) 884-889
19. Carman C.V., Som T., Kim C.M., and Benovic J.L. Binding and phosphorylation of tubulin by G protein-coupled receptor kinases. J. Biol. Chem. 273 (1998) 20308-20316
20. Colloby S.J., Williams E.D., Burn D.J., Lloyd J.J., McKeith I.G., and O'Brien J.T. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 1176-1185
21. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol. Aging 18 (1997) S1-S2
22. Diaz A., Pazos A., Florez J., Ayesta F.J., Santana V., and Hurle M.A. Regulation of mu-opioid receptors, G-protein-coupled receptor kinases and beta-arrestin 2 in the rat brain after chronic opioid receptor antagonism. Neuroscience 112 (2002) 345-353
23. e Lau L.M., Schipper C.M., Hofman A., Koudstaal P.J., and Breteler M.M. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch. Neurol. 62 (2005) 1265-1269
24. Emre M. Dementia associated with Parkinson's disease. Lancet 2 (2003) 229-237
25. Fan X., Zhang J., Zhang X., Yue W., and Ma L. Acute and chronic morphine treatments and morphine withdrawal differentially regulate GRK2 and GRK5 gene expression in rat brain. Neuropharmacology 43 (2002) 809-816
26. Gainetdinov R.R., Bohn L.M., Walker J.K., Laporte S.A., Macrae A.D., Caron M.G., Lefkowitz R.J., and Premont R.T. Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice. Neuron 24 (1999) 1029-1036
27. Gainetdinov R.R., Bohn L.M., Sotnikova T.D., Cyr M., Laakso A., Macrae A.D., Torres G.E., Kim K.M., Lefkowitz R.J., Caron M.G., and Premont R.T. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron 38 (2003) 291-303
28. Gelb D.J., Oliver E., and Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56 (1999) 33-39
29. Grange-Midroit M., Garcia-Sevilla J.A., Ferrer-Alcon M., La Harpe R., Huguelet P., and Guimon J. Regulation of GRK 2 and 6, beta-arrestin-2 and associated proteins in the prefrontal cortex of drug-free and antidepressant drug-treated subjects with major depression. Brain Res. Mol. Brain Res. 111 (2003) 31-41
30. Guigoni C., Aubert I., Li Q., Gurevich V.V., Benovic J.L., Ferry S., Mach U., Stark H., Leriche L., Hakansson K., Bioulac B.H., Gross C.E., Sokoloff P., Fisone G., Gurevich E.V., Bloch B., and Bezard E. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat. Disord. 11 Suppl. 1 (2005) S25-S29
31. Gurevich E.V., Benovic J.L., and Gurevich V.V. Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development. Neuroscience 109 (2002) 421-436
32. Gurevich E.V., Benovic J.L., and Gurevich V.V. Arrestin2 expression selectively increases during neural differentiation. J. Neurochem. 91 (2004) 1404-1416
33. Gurevich V.V., Dion S.B., Onorato J.J., Ptasienski J., Kim C.M., Sterne-Marr R., Hosey M.M., and Benovic J.L. Arrestin interaction with G protein-coupled receptors. Direct binding studies of wild type and mutant arrestins with rhodopsin, b2-adrenergic, and m2 muscarinic cholinergic receptors. J. Biol. Chem. 270 (1995) 720-731
34. Gurevich V.V., and Gurevich E.V. The new face of active receptor bound arrestin attracts new partners. Structure 11 (2003) 1037-1042
35. Gurevich V.V., and Gurevich E.V. The molecular acrobatics of arrestin activation. TIPS 25 (2004) 59-112
36. Gurevich V.V., and Gurevich E.V. Structural basis of arrestin regulation of G protein-coupled receptors. Pharmacol. Ther. 110 (2006) 465-502
37. Hall R.A., and Lefkowitz R.J. Regulation of G protein-coupled receptor signaling by scaffold proteins. Circ. Res. 91 (2002) 672-680
38. Hanson S.M., Francis D.J., Vishnivetskiy S.A., Klug C.S., and Gurevich V.V. Visual arrestin binding to microtubules involves a distinct conformational change. J. Biol. Chem. 281 (2006) 9765-9772
39. Hanson S.M., Francis D.J., Vishnivetskiy S.A., Raman D., Van Eps N., Hubbell W.L., Klug C.S., and Gurevich V.V. Arrestin binding to microtubules involves a distinct conformational change. FASEB J. 20 (2006) A110-A1110
40. Hilker R., Thomas A.V., Klein J.C., Weisenbach S., Kalbe E., Burghaus L., Jacobs A.H., Herholz K., and Heiss W.D. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65 (2005) 1716-1722
41. Horie K., and Insel P.A. Retrovirally mediated transfer of a G protein-coupled receptor kinase (GRK) dominant-negative mutant enhances endogenous calcitonin receptor signaling in chinese hamster ovary cells. GRK inhibition enhances expression of receptors and receptor mRNA. J. Biol. Chem. 275 (2000) 29433-29440
42. Hurle M.A. Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity. J. Neurochem. 77 (2001) 486-492
43. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., Clark C.M., Glosser G., Stern M.B., Gollomp S.M., and Arnold S.E. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54 (2000) 1916-1921
44. Iaccarino G., Rockman H.A., Shotwell K.F., Tomhave E.D., and Koch W.J. Myocardial overexpression of GRK3 in transgenic mice: evidence for in vivo selectivity of GRKs. Am. J. Physiol. 275 (1998) 1298-1306
45. Iaccarino G., Tomhave E.D., Lefkowitz R.J., and Koch W.J. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by b-adrenergic receptor stimulation and blockade. Circulation 98 (1998) 1783-1789
46. Iaccarino G., Lefkowitz R.J., and Koch W.J. Myocardial G protein-coupled receptor kinases: implications for heart failure therapy. Proc. Assoc. Am. Phys. 111 (1999) 399-405
47. Ito K., Nagano-Saito A., Kato T., Arahata Y., Nakamura A., Kawasumi Y., Hatano K., Abe Y., Yamada T., Kachi T., and Brooks D.J. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 125 (2002) 1358-1365
48. Jellinger K.A. Morphological substrates of dementia in parkinsonism. A critical update. J. Neural. Transm. 51 (1997) 57-82
49. Jellinger K.A., Seppi K., Wenning G.K., and Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J. Neural. Transm. 109 (2002) 329-339
50. Joyce J.N., Ryoo H., Gurevich E.V., Adler C., and Beach T. Ventral striatal D(3) receptors and Parkinson's Disease. Parkinsonism Relat. Disord. 7 (2001) 225-230
51. Joyce J.N., Ryoo H.L., Beach T.B., Caviness J.N., Stacy M., Gurevich E.V., Reiser M., and Adler C.H. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res. 955 (2002) 138-152
52. Kang J., Shi Y., Xiang B., Qu B., Su W., Zhu M., Zhang M., Bao G., Wang F., Zhang X., Yang R., Fan F., Chen X., Pei G., and Ma L. A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell 123 (2005) 833-847
53. Kim C.M., Dion S.B., Onorato J.J., and Benovic J.L. Expression and characterization of two beta-adrenergic receptor kinase isoforms using the baculovirus expression system. Receptor 3 (1993) 39-55
54. Kim J., Ahn S., Ren X.R., Whalen E.J., Reiter E., Wei H., and Lefkowitz R.J. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signalling. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 142-1447
55. Kim K.M., Valenzano K.J., Robinson S.R., Yao W.D., Barak L.S., and Caron M.G. Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J. Biol. Chem. 276 (2001) 37409-37414
56. Knopman D.S., Parisi J.E., Salviati A., Floriach-Robert M., Boeve B.F., Ivnik R.J., Smith G.E., Dickson D.W., Johnson K.A., Petersen L.E., McDonald W.C., Braak H., and Petersen R.C. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 62 (2003) 1087-1095
57. Koch W.J., Rockman H.A., Samama P., Hamilton R.A., Bond R.A., Milano C.A., and Lefkowitz R.J. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 268 (1995) 1350-1353
58. Kohout T.A., Lin F.S., Perry S.J., Conner D.A., and Lefkowitz RJ. Beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 1601-1606
59. Krupnick J.G., and Benovic J.L. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 289-319
60. Kunapuli P., Onorato J.J., Hosey M.M., and Benovic J.L. Expression, purification, and characterization of the G protein-coupled receptor kinase GRK5. J. Biol. Chem. 269 (1994) 1099-1105
61. Lefkowitz R.J., and Whalen E.J. Beta-arrestins: traffic cops of cell signaling. Curr. Opin. Cell Biol. 16 (2004) 162-168
62. Lefkowitz R.J., and Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 308 (2005) 512-517
63. Levy G. Dementia in Parkinson's disease challenges the "gold standard". Ann. Neurol. 58 (2005) 663-665
64. Lieberman A. Depression in Parkinson's disease-a review. Acta Neurol. Scand. 113 (2006) 1-8
65. Loudon R.P., and Benovic J.L. Expression, purification, and characterization of the G protein-coupled receptor kinase GRK6. J. Biol. Chem. 269 (1994) 22691-22697
66. Luttrell L.M., Roudabush F.L., Choy E.W., Miller W.E., Field M.E., Pierce K.L., and Lefkowitz R.J. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 2449-2454
67. Maidment I., Fox C., and Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst. Rev. 1 (2006) CD004747
68. Mattila P.M., Rinne J.O., Helenius H., Dickson D.W., and Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. 100 (2000) 285-290
69. McDonald W.M., Holtzheimer PEr, and Byrd E.H. The diagnosis and treatment of depression in Parkinson's disease. Curr. Treat Opinions Neurol. 8 (2006) 245-255
70. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrne E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns A., Miller B.L., Lovestone S., Collerton D., Jansen E.N., Ballard C., de Vos R.A., Wilcock G.K., Jellinger K.A., and Perry R.H. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47 (1996) 1113-1124
71. Ménard L., Ferguson S.S., Barak L.S., Bertrand L., Premont R.T., Colapietro A.M., Lefkowitz R.J., and Caron M.G. Members of the G protein-coupled receptor kinase family that phosphorylate the β2-adrenergic receptor facilitate sequestration. Biochemistry 35 (1996) 4155-4160
72. Miralles A., Asensio V.J., and Garcia-Sevilla J.A. Acute treatment with the cyclic antidepressant desipramine, but not fluoxetine, increases membrane-associated G protein-coupled receptor kinases 2/3 in rat brain. Neuropharmacology 43 (2002) 1249-1257
73. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., and Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991) 479-486
74. Mundell S.J., Luty J.S., Willets J., Benovic J.L., and Kelly E. Enhanced expression of G protein-coupled receptor kinase 2 selectively increases the sensitivity of A2A adenosine receptors to agonist-induced desensitization. Br. J. Pharmacol. 125 (1998) 347-356
75. Mundell S.J., Loudon R.P., and Benovic J.L. Characterization of G protein-coupled receptor regulation in antisense mRNA-expressing cells with reduced arrestin levels. Biochemistry 38 (1999) 8723-8732
76. Muriel M.P., Bernard V., Levey A.I., Laribi O., Abrous D.N., Agid Y., Bloch B., and Hirsch E.C. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Ann. Neurol. 46 (1999) 103-111
77. Nair K.S., Hanson S.M., Mendez A., Gurevich E.V., Kennedy M.J., Shestopalov V.I., Vishnivetskiy S.A., Chen J., Hurley J.B., Gurevich V.V., and Slepak V.Z. Light-dependent redistribution of arrestin in vertebrate rods is an energy-independent process governed by protein-protein interactions. Neuron 46 (2005) 555-567
78. Oakley R.H., Laporte S.A., Holt J.A., Caron M.G., and Barak L.S. Differential affinities of visual arrestin, barrestin1, and barrestin2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 275 (2000) 17201-17210
79. Orsini M.J., and Benovic J.L. Characterization of dominant negative arrestins that inhibit beta-2-adrenergic receptor internalization by distinct mechanisms. J. Biol. Chem. 273 (1998) 34616-34622
80. Ozaita A., Escriba P.V., Ventayol P., Murga C., Mayor F.J., and Garcia-Sevilla J.A. Regulation of G protein-coupled receptor kinase 2 in brains of opiate-treated rats and human opiate addicts. J. Neurochem. (1998) 1249-1257
81. Pan L., Gurevich E.V., and Gurevich V.V. The nature of the arrestin x receptor complex determines the ultimate fate of the internalized receptor. J. Biol. Chem. 278 (2003) 11623-11632
82. Parkkinen L., Kauppinen T., Pirttila T., Autere J.M., and Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann. Neurol. 57 (2005) 82-91
83. Parruti G., Peracchia F., Sallese M., Ambrosini G., Masini M., Rotilio D., and De Blasi A. Molecular analysis of human beta-arrestin-1: cloning, tissue distribution, and regulation of expression, Identification of two isoforms generated by alternative splicing. J. Biol. Chem. 268 (1993) 9753-9761
84. Penela P., Elorza A., Sarnago S., and Mayor F.J. Beta-arrestin- and c-Src-dependent degradation of G-protein-coupled receptor kinase 2. EMBO J. 20 (2001) 5129-5138
85. Penela P., Ribas C., and Mayor F.J. Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell Signal 15 (2003) 973-981
86. Penela P., Murga C., Ribas C., Tutor A.S., Peregrin S., and Mayor F.J. Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc. Res. 69 (2006) 46-56
87. Pierce K., Luttrell L.M., and Lefkowitz R.J. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20 (2001) 1532-1539
88. Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov. Disord. 20 (2005) S77-S82
89. Premont R.T., Koch W.J., Inglese J., and Lefkowitz R.J. Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases. J. Biol. Chem. 269 (1994) 6832-6841
90. Pronin A.N., Morris A.J., Surguchov A., and Benovic J.L. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275 (2000) 26515-26522
91. Ramos-Ruiz R., Penela P., Penn R.B., and Mayor F.J. Analysis of the human G protein-coupled receptor kinase 2 (GRK2) gene promoter: regulation by signal transduction systems in aortic smooth muscle cells. Circulation 101 (2000) 2083-2089
92. Ren X.R., Reiter E., Ahn S., Kim J., Chen W., and Lefkowitz R.J. Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 1448-1453
93. Richard I.H., Papka M., Rubio A., and Kurlan R. Parkinson's disease and dementia with Lewy bodies: one disease or two?. Mov. Disord. 17 (2002) 1161-1165
94. Richardson R.M., and Hosey M.M. Agonist-induced phosphorylation and desensitization of human m2 muscarinic cholinergic receptors in Sf9 insect cells. J. Biol. Chem. 267 (1993) 22249-22255
95. Rockman H.A., Choi D.J., Rahman N.U., Akhter S.A., Lefkowitz R.J., and Koch W.J. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 9954-9959
96. Ryoo H.L., Pierrotti D., and Joyce J.N. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 13 (1998) 788-797
97. Sallese M., Mariggio S., Collodel G., Moretti E., Piomboni P., Baccetti B., and De Blasi A. G protein-coupled receptor kinase GRK4. Molecular analysis of the four isoforms and ultrastructural localization in spermatozoa and germinal cells. J. Biol. Chem. 272 (1997) 10188-10195
98. Sterne-Marr R., Gurevich V.V., Goldsmith P., Bodine R.C., Sanders C., Donoso L.A., and Benovic J.L. Polypeptide variants of beta-arrestin and arrestin3. J. Biol. Chem. 268 (1993) 15640-15648
99. Terwilliger R.Z., Ortiz J., Guitart X., and Nestler E.J. Chronic morphine administration increases beta-adrenergic receptor kinase (beta ARK) levels in the rat locus coeruleus. J. Neurochem. 63 (1994) 1983-1986
100. Tohgo A., Pierce K.L., Choy E.W., Lefkowitz R.J., and Luttrell L.M. Beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J. Biol. Chem. 277 (2002) 9429-9436
101. Tohgo A., Choy E.W., Gesty-Palmer D., Pierce K.L., Laporte S., Oakley R.H., Caron M.G., Lefkowitz R.J., and Luttrell L.M. The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J. Biol. Chem. 278 (2003) 6258-6267
102. Tsuboi Y., and Dickson D.W. Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?. Parkinsonism Relat. Disord. 11 Suppl. 1 (2005) S47-S51
103. Willets J.M., Parent J.L., Benovic J.L., and Kelly E. Selective reduction in A2 adenosine receptor desensitization following antisense-induced suppression of G protein-coupled receptor kinase 2 expression. J. Neurochem. 73 (1999) 1781-1789